![Hans-Gustaf Ljunggren](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hans-Gustaf Ljunggren
Direktor/Vorstandsmitglied bei XNK Therapeutics AB
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gunnar Mattsson | M | 60 |
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | 12 Jahre |
Lena Birgitta Degling Wikingsson | M | 61 |
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | 12 Jahre |
Samuel Duffey | M | 78 |
Vycellix, Inc.
![]() Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | - |
Eva Agneta Edberg | F | 68 |
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | 6 Jahre |
Ted Ingemar Jakob Fjällman | M | 46 |
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | 2 Jahre |
Johan Liwing | M | - |
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | - |
David Berglund | M | - |
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | 3 Jahre |
Stephen Wooding | M | - |
CellProtect Nordic Pharmaceuticals AB
![]() CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | 3 Jahre |
Evren Alici | M | - |
Vycellix, Inc.
![]() Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | - |
Michael J. Keller | M | - |
Vycellix, Inc.
![]() Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | - |
Hugo Petit | M | 54 |
XNK Therapeutics AB
![]() XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweden | 8 | 72,73% |
Vereinigte Staaten | 3 | 27,27% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Hans-Gustaf Ljunggren
- Persönliches Netzwerk